Simbionix
Date | Investors | Amount | Round |
---|---|---|---|
$7.0m | Series C | ||
$120m Valuation: $120m | Acquisition | ||
N/A | $310k | Early VC | |
Total Funding | CAD10.0m |
Related Content
Recent News about Simbionix
EditSimbionix, a division of 3D Systems, specializes in providing advanced 3D simulation solutions designed to enhance clinical training and optimize procedural outcomes. Operating in the healthcare sector, Simbionix serves medical professionals, educational institutions, and healthcare organizations. The company leverages its proprietary software and 3D printing technologies to create patient-specific, diagnostic-quality anatomic models, which are FDA-cleared and meet stringent regulatory requirements. Simbionix's business model revolves around selling its simulation software, 3D printers, and related services, generating revenue through direct sales, subscriptions, and support contracts. By focusing on improving clinical performance through education and collaboration, Simbionix aims to advance medical training and patient care.
Keywords: 3D simulation, clinical training, procedural outcomes, healthcare, medical education, patient-specific models, FDA-cleared, anatomic models, 3D printing, regulatory compliance.